About the Event
Silence Therapeutics (NASDAQ: SLN) announced AstraZeneca will pay the company a $10 million option fee to advance development of an undisclosed program. This is the first product candidate under AZ’s mRNA collaboration with Silence.
Join our webinar with Silence CEO, Craig Tooman, to hear how their mRNAi Gold Platform transforms peoples’ lives by silencing diseases through precision engineered medicines.